Acronym:
RAGNAR
ACTRN/NCT /ethics:
NCT04083976
Scientific title:
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Summary of trial and patient characteristics
| Cancer Type | All cancers | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Solid tumours |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
| Sex | Both | Anticipated Start Date | 2019-11-20 |
| Molecular Target | Anticipated End Date | 2025-07-14 | |
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Solid tumours |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2019-11-20 |
| Anticipated End Date | 2025-07-14 |
Trial Summary
The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) mutations and gene fusions.
Lay Summary
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Sponsor / Cooperative group
Janssen Research & Development LLC
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Dr Chris Karapetis | Not Yet Recruiting |